Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

2618 - Avelumab in patients with metastatic adrenocortical carcinoma (mACC): results from the JAVELIN Solid Tumor trial

Date

10 Sep 2017

Session

Poster display session

Topics

Immunotherapy;  Endocrine Tumours

Presenters

Christophe Le Tourneau

Citation

Annals of Oncology (2017) 28 (suppl_5): v295-v329. 10.1093/annonc/mdx371

Authors

C. Le Tourneau1, C. Zarwan2, C. Hoimes3, D.J. Wong4, S. Bauer5, M. Wermke6, H.J. Grote7, A. von Heydebreck8, K. Chin9, J. Gulley10

Author affiliations

  • 1 Dept Of Medical Oncology, Institut Curie, 75248 cedex5 - Paris/FR
  • 2 Medical Oncology, Lahey Hospital and Medical Center, Burlington/US
  • 3 Hematology And Oncology, Case Western Reserve University and University Hospitals Seidman Cancer Center, 44106 - Cleveland/US
  • 4 Department Of Medicine, University of California, Los Angeles Medical Center, 90024 - Los Angeles/US
  • 5 Dept. Of Medical Oncology, University Hospital Essen Westdeutsches Tumorzentrum, 45122 - Essen/DE
  • 6 Early Clinical Trial Unit, Universitätsklinikum Dresden, 01307 - Dresden/DE
  • 7 Oncology, Merck KGaA, 64293 - Darmstadt/DE
  • 8 Biostatistics, Merck KGaA, Darmstadt/DE
  • 9 Immune-oncology, EMD Serono, Inc, 01821 - Billerica/US
  • 10 Genitourinary Malignancies Branch, National Cancer Institute, Bethesda, MD/US
More

Resources

Abstract 2618

Background

Avelumab is a human anti–PD-L1 IgG1 antibody that has shown promising clinical activity in multiple tumor types, and is approved in the US for the treatment of metastatic Merkel cell carcinoma. Here, we report an updated analysis of avelumab in patients (pts) with mACC, representing the largest prospective monotherapy study performed to date in this rare cancer with limited therapeutic options.

Methods

In a phase 1b cohort (NCT01772004), pts with mACC and prior platinum-based therapy received avelumab at 10 mg/kg IV Q2W until progression, unacceptable toxicity, or withdrawal. Prior and ongoing treatment with mitotane was permitted. Tumors were assessed every 6 wks (RECIST v1.1). Endpoints included safety (NCI-CTCAE v4.0), best overall response, objective response rate (ORR), progression-free survival (PFS), and overall survival (OS).

Results

As of Dec 31, 2016, 50 pts from 6 countries received avelumab for a median of 3.4 mos (0.5–24.8). Median follow-up was 16.5 mos (11.7-27.6); 5 pts (10.0%) remained on treatment. Median age was 50 y (range 21–71) and median time since diagnosis of metastatic disease was 14.5 mos. 24 pts (48.0%) had received ≥2 prior lines of treatment for advanced disease (median 1, range 0–6). 41 pts (82.0%) had a treatment-related adverse event (TRAE) of any grade; the most common (>15%) were nausea (20.0%) and fatigue (18.0%). 8 pts (16.0%) had a grade ≥3 TRAE, of which only increased ALT (4.0%) occurred in > 1 pt. 12 pts (24.0%) had an immune-related AE of any grade. Confirmed ORR was 6.0% (3 partial responses; 95% CI 1.3–16.5); response was ongoing in 1 pt at data cutoff. 21 pts (42.0%) had stable disease as best response (disease control rate 48.0%). Median PFS was 2.6 mos (95% CI 1.4–4.0). Median OS was 10.6 mos (95% CI 7.4–not estimable) and the 12-mo OS rate was 47.0% (95% CI 31.8–60.9). Responses occurred in 2 pts with PD-L1+ tumors and 1 PD-L1 − (≥5% tumor cell cutoff). In PD-L1 + (n = 12) vs PD-L1 − (n = 30) subgroups, median PFS was 5.5 vs 1.7 mos (HR 0.66; 95% CI 0.3–1.4) and median OS was 14.4 vs 11.5 mos (HR 0.82; 95% CI 0.3–2.2), respectively.

Conclusions

Avelumab had a manageable safety profile and demonstrated clinical activity in pts with platinum-treated mACC.

Clinical trial identification

NCT: NCT01772004 Protocol: EMR 100070-001

Legal entity responsible for the study

Pfizer Inc., New York, NY, USA; Merck KGaA, Darmstadt, Germany.

Funding

Funding was provided by Pfizer Inc., New York, NY, USA and Merck KGaA, Darmstadt, Germany.

Disclosure

C. Le Tourneau: Provided a consulting role for MSD, Bristol-Myers Squib, Novartis and AstraZaneca and received honoraria from Merck Serono and AstraZaneca. C. Zarwan: Provided an advisory role for Revere Pharmaceutics and consulting for Perceptive Informatics. C. Hoimes: Provided an advisory role for Seattle Genetics and Eisai, and participated in speaker\'s bureau\'s for Bristol-Myers Squib and Genentech. D.J. Wong: Received research funding from Armo Biosciences, BioMed Valley Discoveries, Roche-Genentech, Merck, EMD Serono, Bristol-Meyers Squibb, KURA Oncology, AstraZeneca. Provided an advisory role for Bristol-Meyers Squibb. S. Bauer: Research support: Novartis, Blueprint Medicines, Ariad; Consultant: GSK, Novartis, Pfizer, Bayer, Fresenius, Lilly, Blueprint Medicines, Deciphera; Honoraria (CME): Pharmamar, GSK, Pfizer, Bayer; Travel support: Pharmamar, Bayer. M. Wermke: Received research funding from Novartis, Pfizer, Roche, Novartis, Roche, Boehringer Ingelheim and Celgene. Provided an advisory role for Roche, Novartis, Bristol-Myers Squib, AstraZeneca and received honoraria from Roche, Novartis, Boehringer Ingelheim. H.J. Grote: Employee of Merck KGaA, Darmstadt, Germany. A. von Heydebreck: Employee of Merck KGaA, Darmstadt, Germany and holds Merck KGaA, Darmstadt, Germany stock. K. Chin: Employee of EMD Serono Inc. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.